ERIS Lifescience

Has ERIS Lifescience declared dividend?

ERIS Lifesciences Ltd has declared a 735% dividend, amounting to ₹7.35 per share, with an ex-date of February 13, 2025. The company has shown strong price returns over various periods, indicating robust performance and potential shareholder value.

ERIS Lifesciences Ltd has declared a 735% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 735%<BR>- Amount per share: 7.35<BR>- Ex-date: 13 Feb 25<BR><BR>Dividend Yield: 0.45%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 11.46%, the dividend return was 0.49%, resulting in a total return of 11.95%.<BR><BR>Over the past year, the price return reached 67.08%, with a dividend return of 0.73%, leading to a total return of 67.81%.<BR><BR>For the two-year period, the price return was 154.22%, the dividend return was 1.09%, culminating in a total return of 155.31%.<BR><BR>In the three-year span, the price return stood at 146.99%, the dividend return was 2.31%, resulting in a total return of 149.3%.<BR><BR>Over the last four years, the price return was 127.14%, with a dividend return of 2.95%, giving a total return of 130.09%.<BR><BR>Finally, in the five-year period, the price return was 223.91%, the dividend return was 5.85%, leading to a total return of 229.76%.<BR><BR>Overall, ERIS Lifesciences has declared a significant dividend, which, combined with strong price returns over multiple periods, indicates a robust performance and potential for shareholder value.

Who are the peers of the ERIS Lifescience?

ERIS Lifescience's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Astrazeneca, Alembic Pharma, Concord Biotech, Jubilant Pharma, and Caplin Point Lab. ERIS Lifescience has a 1-year return of 75.46%, outperforming its peers, with Divi's Lab leading at 51.96% and Cipla at 0.86%.

Peers: The peers of ERIS Lifescience are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Astrazeneca Phar, Alembic Pharma, Concord Biotech, Jubilant Pharmo, and Caplin Point Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Concord Biotech, while Good management risk is found at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Astrazeneca Phar, ERIS Lifescience, Alembic Pharma, and Caplin Point Lab, and Average management risk is noted at Jubilant Pharmo. Growth ratings show Excellent growth at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, ERIS Lifescience, Alembic Pharma, and the rest. Excellent capital structure is noted at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Astrazeneca Phar, ERIS Lifescience, Alembic Pharma, and Caplin Point Lab, while Good capital structure is found at Torrent Pharma, and Average capital structure is seen at Jubilant Pharmo.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while the lowest is Cipla at 0.86%. ERIS Lifescience's 1-year return of 75.46% is significantly higher than both. Additionally, Alembic Pharma and Jubilant Pharmo have negative six-month returns.

Who are in the management team of ERIS Lifescience?

As of March 2022, the management team of ERIS Lifescience includes Amit Indubhushan Bakshi (CMD & Executive Director), Kaushal Kamlesh Shah, Inderjeet Singh Negi, Krishnakumar Vaidyanathan (Executive Director/WTD/Chairman), and four Independent Non-Executive Directors: Sujesh Vasudevan, Prashant Gupta, Rajeev Narotam Dalal, and Kalpana Unadkat. They oversee the company's strategic direction and governance.

As of March 2022, the management team of ERIS Lifescience includes the following individuals:<BR><BR>1. Amit Indubhushan Bakshi - CMD & Executive Director<BR>2. Kaushal Kamlesh Shah - WTD & Executive Director<BR>3. Inderjeet Singh Negi - WTD & Executive Director<BR>4. Krishnakumar Vaidyanathan - Executive Director / WTD / Chairman<BR>5. Sujesh Vasudevan - Independent Non-Executive Director<BR>6. Prashant Gupta - Independent Non-Executive Director<BR>7. Rajeev Narotam Dalal - Independent Non-Executive Director<BR>8. Kalpana Unadkat - Independent Non-Executive Director<BR><BR>This team is responsible for the strategic direction and governance of the company.

What does ERIS Lifescience do?

Eris Lifesciences Ltd manufactures and markets pharmaceutical products and is classified as a Large Cap company. As of March 2025, it reported net sales of ₹7,053 Cr and a net profit of ₹938 Cr.

Overview: <BR>Eris Lifesciences Ltd is engaged in the manufacturing and marketing of pharmaceutical products within the Pharmaceuticals & Biotechnology industry and is categorized as a Large Cap company.<BR><BR>History: <BR>Eris Lifesciences Limited was incorporated on January 25, 2007, and changed its name to 'Eris Lifesciences Private Limited' on February 9, 2007. The company was converted into a Public Limited Company and rebranded as 'Eris Lifesciences Limited' on February 2, 2017. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 7,053 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 938 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 24,168 Cr (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 68.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.42% <BR>Debt-Equity: 0.79 <BR>Return on Equity: 12.35% <BR>Price to Book: 8.31 <BR><BR>Contact Details: <BR>Address: 8th Floor Commerce House -IV, Prahladnagar 100 FT Road Ahmedabad Gujarat : 380015 <BR>Tel: 91-79-30451000 <BR>Email: complianceofficer@erislifesciences. <BR>Website: http://www.eris.co.in

Who are the top shareholders of the ERIS Lifescience?

The top shareholders of ERIS Lifescience include promoter Amit Indubhusan Bakshi with 42.84%, mutual funds holding 16.59%, foreign institutional investors at 8.43%, and the highest public shareholder, Lilac Investments Limited, with 8.79%. Individual investors collectively own 9.16% of the shares.

The top shareholders of ERIS Lifescience include the promoters, who hold a significant majority of the shares. The promoter with the highest holding is Amit Indubhusan Bakshi, owning 42.84% of the company. Additionally, mutual funds hold 16.59% of the shares, represented by 22 schemes, while foreign institutional investors (FIIs) account for 8.43% through 135 different entities. The highest public shareholder is Lilac Investments Limited, which holds 8.79%. Individual investors collectively own 9.16% of the shares.

How big is ERIS Lifescience?

As of 24th July, ERIS Lifesciences Ltd has a market capitalization of 24,385.00 Cr, with recent Net Sales of 2,893.64 Cr and a Net Profit of 352.37 Cr. The company reports Shareholder's Funds of 2,854.36 Cr and Total Assets of 6,744.13 Cr.

As of 24th July, ERIS Lifesciences Ltd has a market capitalization of 24,385.00 Cr, categorizing it as a Large Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 2,893.64 Cr and a Net Profit of 352.37 Cr.<BR><BR>The latest annual period shows Shareholder's Funds of 2,854.36 Cr and Total Assets amounting to 6,744.13 Cr.

Is ERIS Lifescience overvalued or undervalued?

As of September 5, 2025, ERIS Lifescience is considered overvalued with a valuation grade of "expensive," reflected in its high PE ratio of 60.82 and EV to EBITDA ratio of 24.71, especially when compared to peers like Sun Pharma and Cipla, despite a year-to-date return of 26.09% that underperformed against the Sensex's 3.29%.

As of 5 September 2025, the valuation grade for ERIS Lifescience has moved from very expensive to expensive, indicating a slight improvement in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 60.82, an EV to EBITDA ratio of 24.71, and a PEG ratio of 37.14, all of which are significantly higher than industry norms.<BR><BR>In comparison to its peers, Sun Pharma has a PE ratio of 33.33 and an EV to EBITDA of 22.53, while Cipla is more attractively valued with a PE of 23.25 and an EV to EBITDA of 16.37. The high valuation metrics of ERIS Lifescience suggest that it is trading at a premium compared to its peers, which reinforces the conclusion of being overvalued. Notably, despite recent stock performance showing a 26.09% return year-to-date, it has underperformed against the Sensex's 3.29% return during the same period.

How has been the historical performance of ERIS Lifescience?

ERIS Lifescience has shown significant growth, with net sales increasing from 1,074.06 Cr in March 2020 to 2,893.64 Cr in March 2025, and operating profit rising from 376.60 Cr to 1,035.56 Cr. However, profit after tax fluctuated, peaking at 406.11 Cr in March 2022 and declining to 351.84 Cr by March 2025.

Answer:<BR>The historical performance of ERIS Lifescience shows significant growth in net sales and operating profit over the years, with net sales reaching 2,893.64 Cr in March 2025, up from 1,074.06 Cr in March 2020. The operating profit (PBDIT) also increased to 1,035.56 Cr in March 2025 from 376.60 Cr in March 2019. However, profit after tax saw fluctuations, peaking at 406.11 Cr in March 2022 before declining to 351.84 Cr in March 2025. The company's total assets grew from 1,381.39 Cr in March 2020 to 6,744.13 Cr in March 2025, while total liabilities increased from 1,381.39 Cr to 6,744.13 Cr in the same period. Cash flow from operating activities improved significantly, reaching 1,065.00 Cr in March 2025 compared to 271.00 Cr in March 2020.<BR><BR>Breakdown:<BR>ERIS Lifescience has demonstrated a robust upward trend in its financial performance, particularly in net sales, which surged from 1,074.06 Cr in March 2020 to 2,893.64 Cr in March 2025. This growth in revenue is accompanied by a notable increase in operating profit, which rose from 376.60 Cr to 1,035.56 Cr over the same period. Despite this positive trend, profit after tax experienced some volatility, peaking at 406.11 Cr in March 2022 before settling at 351.84 Cr in March 2025. The company's total assets expanded significantly, reflecting its growth strategy, climbing from 1,381.39 Cr to 6,744.13 Cr. Total liabilities mirrored this growth, also increasing to 6,744.13 Cr. Cash flow from operating activities saw a remarkable improvement, indicating enhanced operational efficiency, with figures rising from 271.00 Cr in March 2020 to 1,065.00 Cr in March 2025.

Is ERIS Lifescience technically bullish or bearish?

As of December 1, 2025, ERIS Lifescience's technical trend is neutral with mixed signals, showing a sideways movement influenced by mildly bearish MACD and KST indicators, while moving averages suggest a slight bullish stance on the daily chart.

As of 1 December 2025, the technical trend for ERIS Lifescience has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The MACD is mildly bearish on both weekly and monthly time frames, while the Bollinger Bands show a bearish signal weekly but mildly bullish monthly. The moving averages indicate a mildly bullish stance on the daily chart, contrasting with the bearish signals from the KST on both weekly and monthly time frames. The Dow Theory suggests a mildly bullish trend on the weekly chart, but there is no clear trend on the monthly. Overall, the lack of strong bullish or bearish signals and the sideways trend indicate a neutral stance with no clear strength in either direction.

When is the next results date for ERIS Lifesciences Ltd?

The next results date for ERIS Lifesciences Ltd is 13 February 2026.

The next results date for ERIS Lifesciences Ltd is scheduled for 13 February 2026.

Are ERIS Lifesciences Ltd latest results good or bad?

ERIS Lifesciences Ltd's latest results show record net sales growth of 11% year-on-year, but significant margin compression led to a 17% decline in net profit quarter-on-quarter. While revenue growth is positive, the decline in profitability raises concerns about operational efficiency, suggesting investors should proceed with caution.

ERIS Lifesciences Ltd's latest results present a mixed picture. On one hand, the company achieved record net sales of ₹807.45 crores in Q3 FY26, reflecting an 11.00% increase year-on-year and a 1.90% rise quarter-on-quarter. This indicates solid revenue growth, which is a positive sign.<BR><BR>However, the results also show significant margin compression. The operating margin decreased to 35.16% from 36.48% in the previous quarter, and the profit after tax (PAT) margin fell sharply to 13.59% from 17.02%. This led to a 17.03% decline in consolidated net profit to ₹99.72 crores compared to the previous quarter, although it is up 19.05% year-on-year.<BR><BR>The sequential decline in profitability raises concerns about operational efficiency and cost management, especially in a competitive pharmaceutical sector facing pricing pressures. Analysts are now reassessing the company's near-term prospects due to this margin erosion and the flat financial trend classification.<BR><BR>Overall, while the revenue growth is commendable, the decline in margins and profit suggests that the company is facing challenges that could impact its future performance. Investors may want to approach with caution, considering both the growth potential and the current operational hurdles.

Should I buy, sell or hold ERIS Lifesciences Ltd?

Which are the latest news on ERIS Lifescience?

Why is ERIS Lifesciences Ltd falling/rising?

As of 17-Mar, ERIS Lifesciences Ltd's stock price is at 1,305.05, reflecting a decline and underperformance against moving averages and its sector. Investor interest has waned significantly, and despite some positive financial metrics, the overall outlook remains cautious due to weak growth indicators.

As of 17-Mar, ERIS Lifesciences Ltd's stock price is falling, currently at 1,305.05, which reflects a decrease of 2.55 (-0.2%). The stock has been underperforming, having lost 3.4% over the last three days and is trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This trend indicates a consistent decline in price momentum.<BR><BR>Investor participation has also decreased significantly, with delivery volume dropping by 65.93% compared to the 5-day average, suggesting reduced interest from traders. Additionally, the stock has underperformed its sector by 0.48% today, further contributing to the negative sentiment surrounding it.<BR><BR>Despite some positive factors, such as a high return on capital employed (ROCE) of 16.70% and strong debt servicing capability, the overall outlook remains cautious due to poor long-term growth indicators. The operating profit growth rate of 17.18% over the last five years is considered weak, and recent flat results, including low inventory and debtors turnover ratios, do not inspire confidence. These factors combined have led to a decline in the stock price of ERIS Lifesciences Ltd.

Why is ERIS Lifesciences Ltd falling/rising?

As of 18-Mar, ERIS Lifesciences Ltd's stock price is rising, currently at 1,306.40, reflecting an increase of 21.85 (1.7%). The stock's recent rise follows a trend reversal, supported by strong financial metrics and positive institutional interest, despite declines over the past week and month.

As of 18-Mar, ERIS Lifesciences Ltd's stock price is rising, currently at 1,306.40, reflecting an increase of 21.85 (1.7%). This upward movement follows a trend reversal after three consecutive days of decline. The stock has outperformed its sector by 1.43% today and reached an intraday high of Rs 1,316.9, which is a 2.52% increase.<BR><BR>Despite this positive performance today, the stock has shown a decline over the past week and month, with returns of -3.19% and -2.79%, respectively. However, the year-to-date performance indicates a more significant drop of -13.13%, which is less than the Sensex's decline of -9.99%. <BR><BR>The stock's current rise can be attributed to several factors. The company exhibits high management efficiency with a return on capital employed (ROCE) of 16.70% and a low debt to EBITDA ratio of 1.32 times, indicating a strong ability to service its debt. Additionally, the stock is trading at a discount compared to its peers' average historical valuations, which may attract investors looking for value opportunities. <BR><BR>Furthermore, institutional holdings are high at 27.17%, with an increase of 0.59% over the previous quarter, suggesting confidence from larger investors who typically have better resources to analyze company fundamentals. The stock's profitability has also improved, with a 34.9% increase in profits over the past year, contributing to a positive PEG ratio of 1.3.<BR><BR>In summary, while ERIS Lifesciences Ltd has faced recent declines, the current rise in stock price is supported by a trend reversal, strong financial metrics, and positive institutional interest.

Why is ERIS Lifesciences Ltd falling/rising?

As of 19-Mar, ERIS Lifesciences Ltd's stock price is declining at 1,290.00, down -1.57%, with a significant drop in investor participation and performance below key moving averages, indicating a bearish trend. Despite some management strengths, poor long-term growth prospects and operational challenges are negatively impacting investor sentiment.

As of 19-Mar, ERIS Lifesciences Ltd is experiencing a decline in its stock price, currently at 1,290.00, which reflects a change of -20.55 (-1.57%). The stock opened the day with a loss of -3.43% and reached an intraday low of Rs 1265.65. This downward movement is further supported by the stock's performance over the past week, where it has fallen by -4.52%, significantly underperforming the Sensex, which decreased by -2.40%.<BR><BR>The stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Additionally, there has been a notable decline in investor participation, with delivery volume dropping by -27.16% compared to the 5-day average. The broader sector, Pharmaceuticals & Drugs, has also seen a decline of -2.13%, contributing to the negative sentiment surrounding ERIS Lifesciences Ltd.<BR><BR>Despite some positive factors such as high management efficiency and strong debt servicing capability, the stock's poor long-term growth prospects, evidenced by a low operating profit growth rate of 17.18% over the last five years, are likely influencing investor sentiment negatively. Furthermore, flat results reported in December, along with low inventory and debtors turnover ratios, suggest operational challenges that may deter potential investors. Overall, these factors collectively contribute to the stock's current downward trajectory.

Why is ERIS Lifesciences Ltd falling/rising?

As of 20-Mar, ERIS Lifesciences Ltd's stock price is rising at 1,297.05, but it has declined over the past week and month, with a year-to-date decrease of 13.75%. Despite strong management efficiency and high institutional holdings, concerns about long-term growth and reduced investor participation may limit positive sentiment.

As of 20-Mar, ERIS Lifesciences Ltd's stock price is rising, currently at 1,297.05, with a change of 14.35 (1.12%) upward. Despite this positive movement today, the stock has shown a decline over the past week and month, with returns of -1.63% and -3.36%, respectively. Year-to-date, the stock has decreased by 13.75%, although it has outperformed the benchmark Sensex, which has declined by 12.54% in the same period.<BR><BR>The stock's performance today indicates it has underperformed its sector by 0.58%, and it is trading below its moving averages across various time frames, suggesting a bearish trend. Additionally, investor participation has fallen significantly, with delivery volume decreasing by 35.59% compared to the 5-day average, indicating reduced interest from investors.<BR><BR>On a more positive note, the company demonstrates high management efficiency with a return on capital employed (ROCE) of 16.70% and a low debt-to-EBITDA ratio of 1.32 times, reflecting a strong ability to service its debt. The stock is also trading at a discount compared to its peers, and despite a -4.23% return over the past year, the company's profits have increased by 34.9%, resulting in a PEG ratio of 1.2, which suggests fair valuation.<BR><BR>Furthermore, institutional holdings are relatively high at 27.17%, with an increase of 0.59% over the previous quarter, indicating confidence from larger investors who typically have better resources to analyze the company's fundamentals. However, concerns about long-term growth persist, as operating profit has grown at an annual rate of only 17.18% over the last five years, and recent results have shown flat performance.<BR><BR>In summary, while ERIS Lifesciences Ltd is experiencing a rise in stock price today, the overall trend reflects challenges in investor participation and long-term growth prospects, which may temper enthusiasm despite positive financial metrics.

Why is ERIS Lifesciences Ltd falling/rising?

As of 23-Mar, ERIS Lifesciences Ltd's stock price is at 1,278.50, down 12.6 (-0.98%), underperforming against the Sensex. The stock is in a bearish trend, trading below all key moving averages, with decreasing investor participation and unfavorable long-term growth prospects.

As of 23-Mar, ERIS Lifesciences Ltd's stock price is falling, currently at 1,278.50, which reflects a decrease of 12.6 (-0.98%). The stock has underperformed compared to the benchmark Sensex, which has also seen a decline of 3.72% over the past week and 12.72% over the past month. <BR><BR>Today, the stock reached an intraday low of Rs 1237.9, marking a drop of 4.12%. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. The overall performance in the Pharmaceuticals & Drugs sector has also been negative, with a decline of 3.62%. <BR><BR>Investor participation appears to be decreasing, as evidenced by a drop in delivery volume by 12.96% compared to the 5-day average. Despite some positive factors, such as high management efficiency and strong debt servicing ability, the stock's long-term growth prospects are viewed unfavorably due to flat results and low turnover ratios. These elements contribute to the stock's current downward movement.

Why is ERIS Lifesciences Ltd falling/rising?

As of 24-Mar, ERIS Lifesciences Ltd's stock price has risen to 1,291.30, outperforming the Sensex despite a monthly decline of 6.74%. The company's strong fundamentals and increased institutional holdings suggest potential value for investors.

As of 24-Mar, ERIS Lifesciences Ltd is experiencing a rise in its stock price, currently at 1,291.30, reflecting an increase of 21.0 (1.65%). This upward movement is notable as the stock has outperformed the benchmark Sensex, which has declined by 2.63% over the past week. Additionally, today the stock reached an intraday high of Rs 1295.95, marking a rise of 2.02%.<BR><BR>Despite the positive performance today, the stock has shown a decline of 6.74% over the past month and a year-to-date drop of 14.13%. However, the company exhibits strong fundamentals, including a high Return on Capital Employed (ROCE) of 16.70% and a low Debt to EBITDA ratio of 1.32 times, indicating a strong ability to service its debt. Furthermore, the stock is trading at a discount compared to its peers' average historical valuations, which may attract investors looking for undervalued opportunities.<BR><BR>The increase in institutional holdings, which rose by 0.59% over the previous quarter to 27.17%, also suggests confidence from larger investors who have better resources to analyze the company's fundamentals. This could contribute to the stock's current upward trend, despite the overall poor long-term growth indicated by a flat operating profit growth rate of 17.18% over the last five years.<BR><BR>In summary, while ERIS Lifesciences Ltd has faced challenges in the past months, its recent price rise can be attributed to positive performance today, strong financial metrics, and increased institutional interest, which may signal a potential recovery or value opportunity for investors.

Why is ERIS Lifesciences Ltd falling/rising?

As of 25-Mar, ERIS Lifesciences Ltd's stock price has risen to 1,350.00, up 5.32%, driven by strong trading activity, increased investor participation, and solid financial metrics, including a high ROCE and low Debt to EBITDA ratio. The stock has consistently outperformed its sector and has robust institutional backing.

As of 25-Mar, ERIS Lifesciences Ltd is experiencing a rise in its stock price, currently at 1,350.00, reflecting an increase of 68.2 points or 5.32%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed the sector by 3.43% today and has shown a consecutive gain over the last two days, accumulating a total return of 6.27% during this period. Additionally, the stock reached an intraday high of Rs 1,350, indicating strong trading activity.<BR><BR>Investor participation has also increased, as evidenced by a significant rise in delivery volume, which was up by 170.52% compared to the 5-day average. This suggests heightened interest and confidence among investors in the stock. Furthermore, the company's management efficiency is highlighted by a high Return on Capital Employed (ROCE) of 16.70%, and it has a low Debt to EBITDA ratio of 1.32 times, indicating a strong ability to service its debt.<BR><BR>Moreover, institutional holdings are robust at 27.17%, with an increase of 0.59% over the previous quarter, suggesting that knowledgeable investors are backing the stock. The stock has also demonstrated consistent returns over the last three years, outperforming the BSE500 in each of the last three annual periods, which adds to its appeal.<BR><BR>Overall, the combination of positive trading performance, increased investor participation, strong financial metrics, and institutional backing has contributed to the rising stock price of ERIS Lifesciences Ltd.